QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Status:
RECRUITING
Trial end date:
2030-04-30
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital